• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用深度学习和先进成像生物标志物表征常染色体显性多囊肾病的表型特征。

Characterizing the ADPKD- Phenotypic Signature With Deep Learning and Advanced Imaging Biomarkers.

作者信息

Ghanem Ahmad, Munairdjy Debeh Fadi George, Borghol Abdul Hamid, Zagorec Nikola, Tapia Amanda L, Smith Byron, Paul Stefan, Basit Abdul, AlKhatib Bassel, Nader Nay, Bou Antoun Marie Therese, Gregory Adriana V, Yang Hana, Schauer Rachel S, Dahl Neera K, Hanna Christian, Torres Vicente E, Kline Timothy L, Harris Peter C, Cornec-Le Gall Emilie, Chebib Fouad T

机构信息

Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, Florida, USA.

University Brest, Inserm, UMR 1078, GGB, CHU Brest, Centre de Références Maladies Rénales Héréditaires de L'enfant et de L'adulte MARHEA, F-29200 Brest, France.

出版信息

Kidney Int Rep. 2025 May 7;10(8):2690-2707. doi: 10.1016/j.ekir.2025.04.062. eCollection 2025 Aug.

DOI:10.1016/j.ekir.2025.04.062
PMID:40814641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12348249/
Abstract

INTRODUCTION

ADPKD is the third most common disease-causing variant in autosomal dominant polycystic kidney disease (ADPKD) after ADPKD- and ADPKD-. This study aimed to characterize the clinical presentation, progression, and distinctive imaging phenotype of ADPKD-

METHODS

This retrospective cohort study included patients with disease-causing variants in , nontruncating (), or . Patients were matched by sex (48.1% male), age (mean [SD]: 57.7 ± 13.3 years), and height-adjusted total kidney volume (TKV; htTKV) (median [Q1-Q3]: 572.9 [314.1-1137.9] ml/m). Two predictive models were developed in the development cohort 81): a deep-learning model incorporating cyst-parenchymal surface area (CPSA) and cystic index, and a practical model using percentage of TKV occupied by the 2 largest cysts, with cyst volumes estimated from cyst diameters using the formula . Models were validated in an internal specificity cohort ( = 569) and an external sensitivity cohort ( = 36).

RESULTS

Patients with ADPKD- exhibited fewer (median cyst number: 42) but larger cysts (average cyst volume: 12.1 ml), with 88.9% having no liver cysts, compared with ADPKD- and ADPKD-. The estimated glomerular filtration rate (eGFR) of decline was slower in ADPKD- (-0.69 ml/min per 1.73 m/yr) than in ADPKD- (-1.62, = 0.006) and in ADPKD- (-0.90, = 0.737). The deep-learning model demonstrated an area-under-the-curve (AUC) of 0.949 for distinguishing ADPKD- patients in the development cohort, and 88.9% specificity in the internal cohort. A volume-to-TKV ratio ≥ 18.6% identified ADPKD- with an AUC of 0.814 and demonstrated 72.2% sensitivity in the external cohort.

CONCLUSION

We provide a detailed characterization of the ADPKD phenotype that can be distinguished using a practical or deep-learning segmentation model applicable in diverse clinical settings.

摘要

简介

在常染色体显性多囊肾病(ADPKD)中,ADPKD-是继ADPKD-和ADPKD-之后第三常见的致病变异。本研究旨在描述ADPKD-的临床表现、疾病进展及独特的影像学表型。

方法

这项回顾性队列研究纳入了携带致病变异、非截短型()或的患者。患者按照性别(48.1%为男性)、年龄(平均[标准差]:57.7±13.3岁)和身高校正后的总肾体积(TKV;htTKV)(中位数[四分位数间距]:572.9[314.1 - 1137.9]ml/m)进行匹配。在开发队列(n = 81)中构建了两个预测模型:一个是结合囊肿-实质表面积(CPSA)和囊肿指数的深度学习模型,另一个是使用最大的2个囊肿占TKV的百分比的实用模型,囊肿体积根据囊肿直径使用公式估算。模型在内部特异性队列(n = 569)和外部敏感性队列(n = 36)中进行验证。

结果

与ADPKD-和ADPKD-相比,ADPKD-患者的囊肿数量较少(中位数囊肿数:42个)但囊肿较大(平均囊肿体积:12.1ml),88.9%的患者无肝囊肿。ADPKD-患者的估计肾小球滤过率(eGFR)下降速度较慢(-0.69ml/min per 1.73m²/年),低于ADPKD-(-1.62,P = 0.006)和ADPKD-(-0.90,P = 0.737)。深度学习模型在开发队列中区分ADPKD-患者的曲线下面积(AUC)为0.949,在内部队列中的特异性为88.9%。体积与TKV比值≥18.6%可识别ADPKD-,AUC为0.814,在外部队列中的敏感性为72.2%。

结论

我们提供了ADPKD表型的详细特征,可使用适用于不同临床环境的实用或深度学习分割模型进行区分。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c823/12348249/932b261fb54a/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c823/12348249/f76ba0d89c70/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c823/12348249/a12658b07cd9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c823/12348249/53bf25c9ed71/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c823/12348249/9de905b11b6c/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c823/12348249/b30d8f117d10/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c823/12348249/4a545e525783/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c823/12348249/932b261fb54a/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c823/12348249/f76ba0d89c70/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c823/12348249/a12658b07cd9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c823/12348249/53bf25c9ed71/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c823/12348249/9de905b11b6c/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c823/12348249/b30d8f117d10/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c823/12348249/4a545e525783/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c823/12348249/932b261fb54a/gr6.jpg

相似文献

1
Characterizing the ADPKD- Phenotypic Signature With Deep Learning and Advanced Imaging Biomarkers.利用深度学习和先进成像生物标志物表征常染色体显性多囊肾病的表型特征。
Kidney Int Rep. 2025 May 7;10(8):2690-2707. doi: 10.1016/j.ekir.2025.04.062. eCollection 2025 Aug.
2
Polycystic Kidney Disease, Autosomal Dominant常染色体显性多囊肾病
3
Pkd2 Deficiency in Embryonic Aqp2 + Progenitor Cells Is Sufficient to Cause Severe Polycystic Kidney Disease.PKD2 缺失在胚胎 AQP2+祖细胞中足以导致严重的多囊肾病。
J Am Soc Nephrol. 2024 Apr 1;35(4):398-409. doi: 10.1681/ASN.0000000000000309. Epub 2024 Jan 23.
4
Autosomal Dominant Polycystic Kidney Disease: A Review.常染色体显性多囊肾病:综述
JAMA. 2025 May 20;333(19):1708-1719. doi: 10.1001/jama.2025.0310.
5
Phenotypic outcomes of PKD1 compared with non-PKD1 genetically confirmed autosomal dominant polycystic kidney disease.与经基因确认的非PKD1型常染色体显性多囊肾病相比,PKD1的表型结果。
J Nephrol. 2025 Jan 30. doi: 10.1007/s40620-024-02184-3.
6
Interventions for preventing the progression of autosomal dominant polycystic kidney disease.用于预防常染色体显性遗传性多囊肾病进展的干预措施。
Cochrane Database Syst Rev. 2024 Oct 2;10(10):CD010294. doi: 10.1002/14651858.CD010294.pub3.
7
The impact of a secondary, rare, non-pathogenic PKD1 variant on disease progression in autosomal dominant polycystic kidney disease.一种继发性、罕见、非致病性PKD1变异对常染色体显性多囊肾病疾病进展的影响。
J Nephrol. 2025 Jan 30. doi: 10.1007/s40620-025-02211-x.
8
MicroRNA and renal fibrosis in autosomal dominant polycystic kidney disease: a longitudinal study.微小RNA与常染色体显性多囊肾病中的肾纤维化:一项纵向研究
J Nephrol. 2025 Jan;38(1):153-162. doi: 10.1007/s40620-024-01965-0. Epub 2024 Jul 5.
9
Validation of the Mayo Imaging Classification System for Predicting Kidney Outcomes in ADPKD.验证 Mayo 影像学分类系统在预测 ADPKD 患者肾脏结局中的作用。
Clin J Am Soc Nephrol. 2024 May 1;19(5):591-601. doi: 10.2215/CJN.0000000000000427. Epub 2024 Feb 26.
10
Autosomal Dominant Polycystic Kidney Disease Progression by Variant Type and Molecular Domain Among HALT-PKD Participants.HALT-PKD研究参与者中常染色体显性多囊肾病按变异类型和分子结构域划分的疾病进展情况
Clin J Am Soc Nephrol. 2025 Aug 5. doi: 10.2215/CJN.0000000801.

本文引用的文献

1
Clinical Spectrum and Prognosis of Atypical Autosomal Dominant Polycystic Kidney Disease Caused by Monoallelic Pathogenic Variants of IFT140.由IFT140单等位基因致病变异引起的非典型常染色体显性多囊肾病的临床谱与预后
Am J Kidney Dis. 2025 Apr;85(4):465-476.e1. doi: 10.1053/j.ajkd.2024.10.009. Epub 2024 Dec 26.
2
Biomarkers of Kidney Disease Progression in ADPKD.常染色体显性多囊肾病中肾病进展的生物标志物
Kidney Int Rep. 2024 Jul 14;9(10):2860-2882. doi: 10.1016/j.ekir.2024.07.012. eCollection 2024 Oct.
3
Importance of in Patients with Polycystic Kidney Disease Without a Family History.
在无家族病史的多囊肾病患者中的重要性。 (你提供的原文“Importance of in Patients with Polycystic Kidney Disease Without a Family History.”中“Importance of ”后面似乎缺少内容)
Kidney Int Rep. 2024 Jul 16;9(9):2685-2694. doi: 10.1016/j.ekir.2024.06.021. eCollection 2024 Sep.
4
Heterozygous loss of function variants in IFT140 are associated with polycystic kidney disease.IFT140 中的杂合功能丧失变异与多囊肾病有关。
Am J Med Genet A. 2024 Dec;194(12):e63841. doi: 10.1002/ajmg.a.63841. Epub 2024 Aug 13.
5
Monoallelic pathogenic variants are a common cause of autosomal dominant polycystic kidney disease-spectrum phenotype.单等位基因致病性变异是常染色体显性多囊肾病谱系表型的常见病因。
Clin Kidney J. 2024 Feb 15;17(2):sfae026. doi: 10.1093/ckj/sfae026. eCollection 2024 Feb.
6
Monoallelic Loss-of-Function IFT140 Pathogenic Variants Cause Autosomal Dominant Polycystic Kidney Disease: A Confirmatory Study With Suspicion of an Additional Cardiac Phenotype.单等位基因功能丧失 IFT140 致病性变异导致常染色体显性多囊肾病:伴有心脏表型可疑的确认性研究。
Am J Kidney Dis. 2024 May;83(5):688-691. doi: 10.1053/j.ajkd.2023.08.019. Epub 2023 Oct 14.
7
The Clinical Utility of Genetic Testing in the Diagnosis and Management of Adults with Chronic Kidney Disease.基因检测在慢性肾脏病成人诊断和管理中的临床应用。
J Am Soc Nephrol. 2023 Dec 1;34(12):2039-2050. doi: 10.1681/ASN.0000000000000249. Epub 2023 Oct 5.
8
Certain heterozygous variants in the kinase domain of the serine/threonine kinase NEK8 can cause an autosomal dominant form of polycystic kidney disease.某些丝氨酸/苏氨酸激酶 NEK8 激酶结构域中的杂合变体可导致常染色体显性多囊肾病。
Kidney Int. 2023 Nov;104(5):995-1007. doi: 10.1016/j.kint.2023.07.021. Epub 2023 Aug 19.
9
Utility of new image-derived biomarkers for autosomal dominant polycystic kidney disease prognosis using automated instance cyst segmentation.基于自动实例囊肿分割的新影像衍生生物标志物在常染色体显性多囊肾病预后中的应用。
Kidney Int. 2023 Aug;104(2):334-342. doi: 10.1016/j.kint.2023.01.010. Epub 2023 Feb 1.
10
Exome Sequencing of a Clinical Population for Autosomal Dominant Polycystic Kidney Disease.常染色体显性遗传多囊肾病临床人群外显子组测序。
JAMA. 2022 Dec 27;328(24):2412-2421. doi: 10.1001/jama.2022.22847.